查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423331

2024-2032 年按测试类型（血液检查、影像学测试、肝臟活检）和地区分類的肝炎诊断测试市场报告

Hepatitis Diagnostic Tests Market Report by Test Type (Blood Tests, Imaging Test, Liver Biopsy), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 149 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球肝炎诊断检测市场规模达到58亿美元。展望未来， IMARC Group预计到2032年市场规模将达到88亿美元，2024-2032年复合年增长率（CAGR）为4.5%。由于全球肝炎盛行率不断上升、诊断技术的快速进步、公众意识和筛检措施的提高、政府支持性政策和资金的实施以及健康保险覆盖范围和报销政策的扩大，该市场正在经历强劲增长。

肝炎诊断测试市场分析：

市场成长与规模：在全球肝炎盛行率上升、诊断技术快速进步以及健康保险覆盖范围和报销政策扩大的推动下，市场正在稳定成长。

主要市场驱动因素：影响市场成长的主要驱动因素包括肝炎发病率的上升、检测方法的快速进步、全球范围内对肝炎预防和治疗的认识不断提高以及政府倡议和资金的实施。

主要市场趋势：主要市场趋势涉及在技术创新的推动下向非侵入性和快速检测方法的持续转变。此外，人们越来越关注床边检测（POC​​T）和个人化医疗，以加强肝炎的早期检测和管理，这也促进了市场的成长。

地理趋势：北美因其先进的医疗保健系统和高认知水平而引领市场。在医疗基础设施不断完善和政府支持性措施实施的推动下，其他地区也出现了显着增长。

竞争格局：市场的特点是主要参与者积极参与，他们专注于研发（R＆D）以引入先进的诊断技术。此外，公司正在进行策略合作、合併和收购，以扩大市场份额并增强产品组合。

挑战与机会：市场面临各种挑战，例如医疗保健取得的差异，特别是在欠发达地区，以及对具有成本效益的检测解决方案的需求。然而，不断涌现的创新以及医疗保健服务向新兴市场的扩张正在为市场成长创造新的机会。

肝炎诊断测试市场趋势：

全球肝炎盛行率不断上升

乙型肝炎和丙型肝炎等肝炎盛行率的增加是推动市场成长的主要因素之一。此外，人们对早期肝炎无症状性质的认识不断增强，增加了对诊断测试的需求，从而促进了市场的成长。除此之外，透过输血传播、不安全注射操作以及出生期间母婴传播的病例不断增加，正在推动市场成长。同时，对肝炎患者的早期诊断和定期监测的需求不断增加，以控制疾病并防止其进展到肝硬化和肝细胞癌等严重阶段，这正在促进市场的成长。与此一致的是，由于检测病毒是否存在、评估肝功能和监测治疗效果的必要性，对诊断测试的需求不断增加，正在促进市场成长。

诊断技术的快速进步

测试方法的快速技术进步和创新，导致更准确、更有效率、侵入性更小的测试的发展，正在促进市场成长。此外，现代诊断工具的发展，如新一代定序（NGS）、即时聚合酶炼式反应（PCR）和快速诊断测试（RDT），可提供更快的结果、更高的灵敏度和特异性，正在发挥作用。生长诱导因子。它们提高了肝炎诊断的准确性并减少了获得结果所需的时间。除此之外，即时检测（POC​​T）的快速进步使得在传统实验室环境之外进行肝炎检测成为可能，正在推动市场成长。除此之外，在公共和私营部门大量投资的支持下，为满足医疗保健提供者和患者不断变化的需求而进行的诊断技术研发（R＆D）正在推动市场成长。

提高疾病意识和教育活动

人们对肝炎及其影响的认识不断提高，导致广泛的筛检和检测，是推动市场成长的主要因素之一。与此一致，各政府卫生机构、非营利组织 (NGO) 和医疗保健提供者越来越关注教育大众与肝炎相关的风险以及早期诊断和治疗的重要性，这正在促进市场成长。同时，多项宣传活动的推出，促进个人接受自愿检测，也刺激了市场的成长。此外，人们不断努力提高对该疾病的普遍了解，例如不安全的注射做法、未经筛检的输血和无保护的性接触，也促进了市场的成长。

落实政府各项倡议

政府采取各种措施来提高肝炎诊断服务的覆盖范围和效率是加强市场成长的主要因素。此外，对研究、诊断设施开发以及对国家肝炎控制计划的支持不断增加的投资正在推动市场的成长。除此之外，与国际组织不断加强合作，制定和实施肝炎预防、诊断和治疗策略，确保在各种医疗保健环境中进行高品质检测，这为市场成长提供了相当大的推动力。此外，政府资助有助于补贴诊断测试的费用，使更广泛的人群更容易获得这些测试。

扩大医疗保险覆盖范围和报销政策

医疗保险覆盖率的扩大和优惠报销政策的製定是有利于市场成长的关键驱动力。此外，人们越来越认识到肝炎是一个公共卫生问题，促使健康保险提供者将肝炎诊断测试纳入其承保服务的一部分，从而扩大了市场的成长。除此之外，政府资助的保险计划的推出，涵盖肝炎检测，同时鼓励个人寻求早期诊断，正在促进市场成长。此外，人们对报销政策的日益关注，有助于医疗保健提供者向患者推荐测试，预计将推动市场成长。报销可以激励实验室和诊断中心提供更广泛的肝炎检测，从而提高先进检测选项的可用性。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 资料来源
    • 主要资源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球肝炎诊断测试市场

  • 市场概况
  • 市场业绩
  • COVID-19 的影响
  • 市场区隔：按测试类型
  • 市场区隔：按地区
  • 市场预测
  • SWOT分析
    • 概述
    • 优势
    • 弱点
    • 机会
    • 威胁
  • 价值链分析
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价格分析

第 6 章：市场区隔：按测试类型

  • 血液检查
    • 市场走向
    • 市场预测
  • 影像学检查
    • 市场走向
    • 市场预测
  • 肝臟活检
    • 市场走向
    • 市场预测

第 7 章：市场区隔：按地区

  • 北美洲
    • 市场走向
    • 市场预测
  • 亚太地区
    • 市场走向
    • 市场预测
  • 欧洲
    • 市场走向
    • 市场预测
  • 中东和非洲
    • 市场走向
    • 市场预测
  • 拉丁美洲
    • 市场走向
    • 市场预测

第 8 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Siemens AG
    • Abbott Laboratories
    • MedMira Inc
    • Qiagen GmbH
    • Beckman Coulter Inc (Danaher Corporation)
    • F. Hoffmann- La Roche AG
    • Diasorin SpA
    • bioMeriuex SA
    • Hologic Inc
    • Bio-Rad Laboratories Inc
Product Code: SR112024A1132

Abstract

The global hepatitis diagnostic tests market size reached US$ 5.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.8 Billion by 2032, exhibiting a growth rate (CAGR) of 4.5% during 2024-2032. The market is experiencing robust growth, driven by the rising prevalence of hepatitis across the globe, rapid technological advancements in diagnostics, increasing public awareness and screening initiatives, implementation of supportive government policies and funding, and the expansion of health insurance coverage and reimbursement policies.

Hepatitis Diagnostic Tests Market Analysis:

Market Growth and Size: The market is witnessing stable growth, driven by the rising prevalence of hepatitis across the globe, rapid advancements in diagnostic technologies, and the expansion of health insurance coverage and reimbursement policies.

Major Market Drivers: Key drivers influencing the market growth include the growing incidence of hepatitis, rapid advancements in testing methods, rising awareness about hepatitis prevention and treatment across the globe, and the imposition of government initiatives and funding.

Key Market Trends: The key market trends involve the ongoing shift towards non-invasive and rapid testing methods, driven by technological innovation. Additionally, the increasing focus on point-of-care testing (POCT) and personalized medicine to enhance early detection and management of hepatitis, is bolstering the market growth.

Geographical Trends: North America leads the market due to its advanced healthcare system and high awareness levels. Other regions are also showing significant growth, fueled by rising healthcare infrastructure and implementation of supportive government initiatives.

Competitive Landscape: The market is characterized by the active involvement of key players who are focusing on research and development (R&D) to introduce advanced diagnostics. Furthermore, companies are engaging in strategic partnerships, mergers, and acquisitions to expand their market presence and enhance product portfolios.

Challenges and Opportunities: The market faces various challenges, such as disparities in healthcare access, particularly in underdeveloped regions, and the need for cost-effective testing solutions. However, the rising innovation, and expansion of healthcare services into emerging markets are creating new opportunities for the market growth.

Hepatitis Diagnostic Tests Market Trends:

Increasing prevalence of hepatitis across the globe

The increasing prevalence of hepatitis, such as hepatitis B and C, is one of the major factors propelling the market growth. Moreover, the growing awareness about the asymptomatic nature of early-stage hepatitis, boosting the need for diagnostic tests, is catalyzing the market growth. Besides this, the burgeoning cases of transmission through blood transfusion, unsafe injection practices, and mother-to-child transmission during birth, are fueling the market growth. Along with this, the rising need for early diagnosis and regular monitoring of patients with hepatitis for managing the disease and preventing its progression to severe stages, such as liver cirrhosis and hepatocellular carcinoma, is catalyzing the market growth. In line with this, the increasing demand for diagnostic tests, driven by the necessity to detect the presence of the virus, assess liver function, and monitor the effectiveness of treatment, is enhancing the market growth.

Rapid advancements in diagnostic technologies

The rapid technological advancements and innovations in testing methodologies, leading to the development of more accurate, efficient, and less invasive tests, are fostering the market growth. Moreover, the development of modern diagnostic tools, such as next-generation sequencing (NGS), real-time polymerase chain reaction (PCR), and rapid diagnostic tests (RDTs) that offer faster results with higher sensitivity and specificity, are acting as a growth-inducing factor. They enhance the accuracy of hepatitis diagnosis and reduce the time required to obtain results. In addition to this, rapid advancements in point-of-care testing (POCT), making it possible to conduct hepatitis tests outside traditional laboratory settings, are fueling the market growth. Besides this, the ongoing research and development (R&D) in diagnostic technologies, supported by substantial investments from public and private sectors, to meet the evolving needs of healthcare providers and patients is driving the market growth.

Rising disease awareness and educational campaigns

The increasing awareness about hepatitis and its implications, leading to widespread screening and testing, is one of the major factors propelling the market growth. In line with this, the growing focus of various governmental health bodies, non-profit organizations (NGOs), and healthcare providers to educate the public about the risks associated with hepatitis and the importance of early diagnosis and treatment is bolstering the market growth. Along with this, the introduction of several awareness campaigns promoting individuals to undergo voluntary testing is stimulating the market growth. Furthermore, the rising efforts to increase the general understanding of the disease, such as unsafe injection practices, unscreened blood transfusions, and unprotected sexual contact, are contributing to the market growth.

Implementation of various government initiatives

The imposition of various government initiatives to enhance the reach and efficiency of hepatitis diagnostic services is a major factor strengthening the market growth. Moreover, the increasing investment in research, development of diagnostic facilities, and support for national hepatitis control programs, is fueling the market growth. In addition to this, the growing collaborations with international organizations to develop and implement strategies for hepatitis prevention, diagnosis, and treatment that ensure high-quality testing across various healthcare settings are providing a considerable boost to the market growth. Additionally, government funding aids in subsidizing the cost of diagnostic tests, making them more accessible to a broader section of the population.

Expansion of health insurance coverage and reimbursement policies

The expansion of health insurance coverage and the development of favorable reimbursement policies are key drivers favoring the market growth. Moreover, the increasing recognition of hepatitis as a public health issue, prompting health insurance providers to include hepatitis diagnostic tests as part of their covered services, is amplifying the market growth. Besides this, the introduction of government-funded insurance schemes that cover hepatitis testing while encouraging individuals to seek early diagnosis is catalyzing the market growth. Furthermore, the growing focus on your reimbursement policies, facilitating healthcare providers to recommend the tests to their patients, is anticipated to drive the market growth. Reimbursement incentivizes laboratories and diagnostic centers to offer a wider range of hepatitis tests, enhancing the availability of advanced testing options.

Hepatitis Diagnostic Tests Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on test type.

Breakup by Test Type:

Blood Tests

Imaging Test

Liver Biopsy

Blood tests accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the test type. This includes blood tests, imaging test, and liver biopsy. According to the report, blood tests represented the largest segment.

Blood tests hold the largest market share due to their widespread availability, ease of use, and cost-effectiveness. They include enzyme-linked immunosorbent assay (ELISA), polymerase chain reaction (PCR), and liver function tests to detect the presence of hepatitis viruses and assess liver damage. Moreover, the high sensitivity and specificity of the tests, making them the first line of diagnosis in most healthcare settings, is boosting the market growth. Additionally, rapid advancements in blood testing technologies, such as rapid diagnostic tests and point-of-care testing (POCT) devices, are anticipated to drive the market growth. Besides this, the increasing utilization of blood tests for large-scale screening programs, especially in areas with high prevalence rates, is bolstering the market growth.

Imaging tests include methods such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI). They are utilized to assess the extent of liver damage in chronic hepatitis cases and to detect conditions like liver cirrhosis or liver cancer. Moreover, the growing importance of imaging tests in the staging of liver disease and guiding decisions regarding the need for more invasive procedures is favoring the market growth.

Liver biopsy involves the extraction of a small liver tissue sample for microscopic examination, providing detailed information about the extent of liver inflammation and fibrosis. They are employed in cases where blood and imaging tests are inconclusive or to assess the severity of liver damage more accurately. Moreover, liver biopsies offer critical insights in complex cases, influencing treatment decisions and management of chronic hepatitis patients.

Breakup by Region:

North America

Asia Pacific

Europe

Middle East and Africa

Latin America

North America leads the market, accounting for the largest hepatitis diagnostic tests market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, the Middle East and Africa and Latin America. According to the report, North America accounted for the largest market share.

North America dominates the market due to its advanced healthcare infrastructure, high awareness levels about hepatitis, and substantial investment in healthcare. Moreover, the widespread adoption of cutting-edge diagnostic technologies, comprehensive screening programs, and robust government policies supporting hepatitis research and public health initiatives in the region are favoring the market growth. Along with this, the growing focus on early detection and prevention, driven by collaborations between healthcare providers, government agencies, and private organizations, is creating a positive outlook for the market growth. Besides this, the heightened research and development (R&D) activities, contributing to the introduction of innovative diagnostic solutions, are fueling the market growth.

The Asia Pacific region market is rapidly growing due to the high prevalence of hepatitis in the region, coupled with improving healthcare infrastructure, increasing public and private healthcare expenditure, and rising awareness about hepatitis and its implications. Moreover, the implementation of several government-funded large-scale screening and vaccination programs is bolstering the market growth.

Europe's hepatitis diagnostic tests market is growing, attributed to its well-established healthcare systems, high awareness of hepatitis, and strong government support for healthcare initiatives. Moreover, the widespread implementation of hepatitis screening and vaccination programs, is fueling the market growth. Besides this, the presence of leading healthcare companies and advanced research facilities in the region, contributing to the development and adoption of innovative diagnostic technologies, is fostering the market growth.

In Latin America, the hepatitis diagnostic tests market is growing, driven by the increasing prevalence of hepatitis. Moreover, the rising efforts to improve healthcare infrastructure and access to medical services are contributing to the market growth. Along with this, the growing focus by the governments and healthcare organizations in the region on awareness campaigns and improving diagnostic and treatment services for hepatitis is enhancing the market growth.

The market in the Middle East and Africa is evolving, with an increasing focus on addressing hepatitis. Moreover, the rising focus on enhancing healthcare services, with an emphasis on infectious disease control and prevention, is creating a positive outlook for the market. Additionally, the growing investment in healthcare and the adoption of modern diagnostic technologies are contributing to the market growth.

Leading Key Players in the Hepatitis Diagnostic Tests Industry:

The major players are engaged in a range of strategic activities to strengthen their market positions. They are investing in research and development (R&D) to introduce more advanced, accurate, and user-friendly diagnostic tests. Moreover, some companies are focusing on developing rapid and non-invasive testing methods that can provide quicker results with high accuracy. Besides this, they are involved in collaborations and partnerships with healthcare organizations, government bodies, and research institutions to enhance their product offerings and expand their geographical reach. Additionally, the leading firms are participating in awareness campaigns and educational programs to increase public knowledge about hepatitis and the importance of early diagnosis.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Siemens AG

Abbott Laboratories

MedMira Inc

Qiagen GmbH

Beckman Coulter Inc (Danaher Corporation)

F. Hoffmann- La Roche AG

Diasorin S.p.A

bioMeriuex SA

Hologic Inc.

Bio-Rad Laboratories Inc.

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

In May 2023, Beckman Coulter Inc (Danaher Corporation) unveiled its next-generation immunoassay analyzer and the DxI 9000 Immunoassay Analyzer with increased assay development sensitivity.

In November 2023, Diasorin announced the development of the first fully automated diagnostic test for hepatitis delta virus (HDV) on the Diasorin LIAISON XL immunoassay system in the United States.

In May 2022, Abbott launched the HBsAg next qualitative solution in India that improved and enhanced the identification of the Hepatitis B virus (HBV).

Key Questions Answered in This Report

  • 1. What was the size of the global hepatitis diagnostic tests market in 2023?
  • 2. What is the expected growth rate of the global hepatitis diagnostic tests market during 2024-2032?
  • 3. What are the key factors driving the global hepatitis diagnostic tests market?
  • 4. What has been the impact of COVID-19 on the global hepatitis diagnostic tests market?
  • 5. What is the breakup of the global hepatitis diagnostic tests market based on the test type?
  • 6. What are the key regions in the global hepatitis diagnostic tests market?
  • 7. Who are the key players/companies in the global hepatitis diagnostic tests market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hepatitis Diagnostic Tests Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Breakup by Test Type
  • 5.5 Market Breakup by Region
  • 5.6 Market Forecast
  • 5.7 SWOT Analysis
    • 5.7.1 Overview
    • 5.7.2 Strengths
    • 5.7.3 Weaknesses
    • 5.7.4 Opportunities
    • 5.7.5 Threats
  • 5.8 Value Chain Analysis
  • 5.9 Porters Five Forces Analysis
    • 5.9.1 Overview
    • 5.9.2 Bargaining Power of Buyers
    • 5.9.3 Bargaining Power of Suppliers
    • 5.9.4 Degree of Competition
    • 5.9.5 Threat of New Entrants
    • 5.9.6 Threat of Substitutes
  • 5.10 Price Analysis

6 Market Breakup by Test Type

  • 6.1 Blood Tests
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Imaging Test
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Liver Biopsy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Middle East and Africa
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Latin America
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Competitive Landscape

  • 8.1 Market Structure
  • 8.2 Key Players
  • 8.3 Profiles of Key Players
    • 8.3.1 Siemens AG
    • 8.3.2 Abbott Laboratories
    • 8.3.3 MedMira Inc
    • 8.3.4 Qiagen GmbH
    • 8.3.5 Beckman Coulter Inc (Danaher Corporation)
    • 8.3.6 F. Hoffmann- La Roche AG
    • 8.3.7 Diasorin S.p.A
    • 8.3.8 bioMeriuex SA
    • 8.3.9 Hologic Inc
    • 8.3.10 Bio-Rad Laboratories Inc

List of Figures

  • Figure 1: Global: Hepatitis Diagnostic Tests Market: Major Drivers and Challenges
  • Figure 2: Global: Hepatitis Diagnostic Tests Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hepatitis Diagnostic Tests Market: Breakup by Test Type (in %), 2023
  • Figure 4: Global: Hepatitis Diagnostic Tests Market: Breakup by Region (in %), 2023
  • Figure 5: Global: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 6: Global: Hepatitis Diagnostic Tests Industry: SWOT Analysis
  • Figure 7: Global: Hepatitis Diagnostic Tests Industry: Value Chain Analysis
  • Figure 8: Global: Hepatitis Diagnostic Tests Industry: Porter's Five Forces Analysis
  • Figure 9: Global: Hepatitis Diagnostic Tests (Blood Test) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hepatitis Diagnostic Tests (Blood Tests) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hepatitis Diagnostic Tests (Imaging Test) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hepatitis Diagnostic Tests (Imaging Test) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hepatitis Diagnostic Tests (Liver Biopsy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: North America: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: North America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Asia Pacific: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Asia Pacific: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Europe: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Europe: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Middle East and Africa: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Middle East and Africa: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Latin America: Hepatitis Diagnostic Tests Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Latin America: Hepatitis Diagnostic Tests Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

  • Table 1: Global: Hepatitis Diagnostic Tests Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
  • Table 3: Global: Hepatitis Diagnostic Tests Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 4: Global: Hepatitis Diagnostic Tests Market: Competitive Structure
  • Table 5: Global: Hepatitis Diagnostic Tests Market: Key Players